Ceritinib-d7
Product Specifications
UNSPSC Description
Ceritinib-d7 is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].
Target Antigen
Anaplastic lymphoma kinase (ALK); IGF-1R; Insulin Receptor; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Others;Protein Tyrosine Kinase/RTK
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Endocrinology
Purity
98.00
Solubility
10 mM in DMSO
Smiles
CC1=C(C2CCNCC2)C=C(OC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])C(NC3=NC=C(Cl)C(NC4=CC=CC=C4S(=O)(C(C)C)=O)=N3)=C1
Molecular Weight
565.18
References & Citations
[1]Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Clinical Information
No Development Reported
CAS Number
1632484-77-5
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
